PHGDH RNA-Binding Domain Small Molecule Ranking — Cycle 4 Progress Report [SCORING & FLAGGING]

cycle_3 | index | cycle_5

---

PHGDH RNA-Binding Domain Small Molecule Ranking — Cycle 4 Progress Report [SCORING & FLAGGING]

Executive Summary

No new data was added this cycle. This is the fourth consecutive cycle with zero new high-relevance sources, zero new entities, and zero ranking differentiation. All 50 scored entities retain total_score = 0.50 due to persistent MCDA tooling failures (drug_likeness and admet_safety unavailable; rbd_binding_affinity and selectivity_over_act unassessable). Rankings remain non-discriminatory — no differentiation achieved. The Learner agent found 0 sources for the fourth time. The current research direction is EXHAUSTED. No further cycles will change the outcome. A fundamentally different approach is required: either de novo computational design, wet-lab collaboration for RBD binding assays, or abandonment of the RBD-selective ligand hypothesis.

Research Progress

What Was Accomplished

• Planner: Created Cycle 4 plan (completed in 34s, $0.00)
• Learner: Searched databases (completed in 6s, $0.00). Hit session limit again
• Executor: Generated 1 ranking artifact (cycle_4_ranking.csv) with 50 entities; executed in 12s ($0.00)

What Failed

• Learner: 0 high-relevance sources found. Fourth consecutive failure
• Executor MCDA: drug_likeness and admet_safety tools remain non-functional. rbd_binding_affinity and selectivity_over_act not populated for any entity. All 50 entities received fallback 0.5 scores

Net Change from Cycle 3

Zero new sources, entities, or ranking differentiation. Identical output.

Key Findings

[Output] Cycle 4 Ranking — Fallback (Tool Failures)

cycle_4_ranking.csv

rank	name	drug_likeness	admet_safety	total_score
1	design_compound_6	0	0	0.50
2	5ofw	0	0	0.50
3	118796328	0	0	0.50
4	4674993	0	0	0.50
5	2g76	0	0	0.50
6	5n53	0	0	0.50
7	5n6c	0	0	0.50
8	5nzo	0	0	0.50
9	5nzp	0	0	0.50
10	5nzq	0	0	0.50
11	5ofm	0	0	0.50
12	5ofv	0	0	0.50
13	6cwa	0	0	0.50
14	design_compound_2	0	0	0.50
15	6plf	0	0	0.50
16	6plg	0	0	0.50
17	6rih	0	0	0.50
18	6rj2	0	0	0.50
19	6rj3	0	0	0.50
20	6rj5	0	0	0.50
21	6rj6	0	0	0.50
22	7cvp	0	0	0.50
23	7dkm	0	0	0.50
24	7ewh	0	0	0.50
25	227328	0	0	0.50
26	BDBM549366	0	0	0.50
27	D-3-phosphoglycerate dehydrogenase	0	0	0.50
28	NEISSERIA MENINGITIDIS NEISSERIAL HEPARI…	0	0	0.50
29	design_compound_10	0	0	0.50
30	design_compound_3	0	0	0.50
31	design_compound_15	0	0	0.50
32	unknown	0	0	0.50
33	unknown	0	0	0.50
34	unknown	0	0	0.50
35	unknown	0	0	0.50
36	unknown	0	0	0.50
37	unknown	0	0	0.50
38	unknown	0	0	0.50
39	THROMBIN BINDING APTAMER	0	0	0.50
40	unknown	0	0	0.50
41	unknown	0	0	0.50
42	unknown	0	0	0.50
43	71524860	0	0	0.50
44	BDBM50519121	0	0	0.50
45	BDBM50652792	0	0	0.50
46	BDBM50512584	0	0	0.50
47	HUMAN C1-ESTERASE INHIBITOR	0	0	0.50
48	WOUND MATRIX, SMALL INTESTINAL SUBMUCOSA	0	0	0.50
49	NEISSERIA MENINGITIDIS FACTOR H BINDING …	0	0	0.50
50	7va1	0	0	0.50

The Cycle 4 ranking is identical to Cycles 1, 2, and 3: all 50 entities scored total_score = 0.50, providing zero discrimination. The #1 ranked entity, design_compound_6, holds this position solely due to alphabetical ordering in the fallback — it has no measurable advantage over any other entity. The top three entities (design_compound_6, 5ofw, 118796328) share identical metrics across all four criteria (drug_likeness=0, admet_safety=0, rbd_binding_affinity unassessable, selectivity_over_act unassessable), making the ranking arbitrary. A counter-intuitive finding persists: known PHGDH active-site inhibitors NCT-503 (CID 118796328) and CBR-5884 (CID 4674993) rank 3rd and 4th despite having no RBD binding evidence whatsoever. Multiple non-drug entries (e.g., NEISSERIA MENINGITIDIS, HUMAN C1-ESTERASE INHIBITOR, WOUND MATRIX) remain in the candidate set and should be excluded.

Quality Assessment

Assessor Feedback (Cycle 3): NIH Score: 5, Composite: 0.44 — “Declining performance trend detected. Consider resetting agent strategy.” This assessment is now stale and does not reflect the four-cycle failure pattern. MCDA validity remains provisional with zero assessable criteria across all four cycles. The ranking table is structurally complete but informationally empty after four identical cycles. The declining composite score (0.53 → 0.48 → 0.44) correctly reflects the trajectory, but the system has not acted on the recommendation to reset strategy.

Budget Status

Metric	Value
Total Budget	$10.00
Spent This Cycle	$0.9612
Cumulative Spent	$3.8431
Budget Used	9.61% (per-cycle)
Remaining	$6.1569
Cycles Remaining	1 of 5
Projected Avg/Cycle	$0.96

Budget is healthy but yielding zero usable data — cost-per-actionable-finding remains undefined after four cycles. The remaining $6.16 will produce one more identical cycle if the current approach continues.

Issues & Risks

Critical Issues

1. Four-cycle data stagnation: No new data in Cycles 1-4. The research question is unanswerable with available data sources and tooling
2. MCDA tool failures: drug_likeness and admet_safety tools have never produced a valid score. rbd_binding_affinity and selectivity_over_act are unassessable for all entities
3. Session limit hits: Learner agent repeatedly hitting session limits, limiting search capacity

Risks

1. Sunk cost fallacy: Continuing Cycle 5 will consume $0.96 for identical output
2. Stale NIH score: The Cycle 3 NIH=5 score does not reflect the four-cycle failure and may give false confidence
3. Non-drug entities in candidate set: NEISSERIA MENINGITIDIS, HUMAN C1-ESTERASE INHIBITOR, WOUND MATRIX are not drug candidates and should never have been scored

Next Steps

The current research direction is EXHAUSTED. No further cycles will change the outcome. The following actions are required:

1. Abandon current approach: The RBD-selective ligand hypothesis cannot be tested with public databases and current MCDA tooling. Four cycles of identical results confirm this
2. Pivot to de novo design: If RBD binding is a genuine therapeutic target, invest remaining budget in molecular docking simulations against experimentally resolved RBD structures, not database mining
3. Wet-lab validation: The only path to new data is experimental RBD binding assays. Partner with a structural biology lab to screen compounds against PHGDH RBD directly
4. Exclude non-drug entities: Before any continuation, remove NEISSERIA MENINGITIDIS, HUMAN C1-ESTERASE INHIBITOR, WOUND MATRIX, and other non-drug entries from the candidate set
5. Reset MCDA tooling: drug_likeness and admet_safety tools must be fixed or replaced before any meaningful scoring can occur

Do NOT run Cycle 5 with the same approach — it will produce identical results.

Best Pick This Cycle

DATA EXHAUSTED — No Best Pick Possible

After four consecutive cycles with identical output, no candidate can be identified as a “best pick” with any scientific validity. design_compound_6 ranks #1 solely due to alphabetical ordering in the fallback scoring system — it has no measurable advantage over any other entity. All 50 candidates share identical metrics: drug_likeness=0, admet_safety=0, rbd_binding_affinity unassessable, selectivity_over_act unassessable.

Confidence Level: ZERO. This ranking is not a finding — it is an artifact of incomplete data and broken tooling.

The only defensible conclusion is that no RBD-selective PHGDH ligand candidates exist in the public databases searched, or if they do, the current tooling cannot identify them. Continuing to rank entities with zero information content serves no scientific purpose.

Governance Status

Per-Agent G/Y/R Alert Levels

Agent	Status	Cost	Time
PLANNER	GREEN	$0.0000	34s
LEARNER	YELLOW	$0.0000	6s
EXECUTOR	YELLOW	$0.0000	12s

A.G.E. Scores

Scale	Score	Target	Status
NIH (1-9, lower=better)	5	≤ 4 by iter 10	NEAR TARGET
Composite	0.44	improving	DECLINING
Trend	0.53 → 0.48 → 0.44	≥ 0	FAILING

MCDA Validity

Field	Value
overall_verdict	provisional
entities_scored	50
criteria_in_spec	4
assessable_criteria	(none)
tool_unavailable	[‘drug_likeness’, ‘admet_safety’] — all-null (tool failed); kept in MCDA with 0.5 neutral fill
unassessable	[‘rbd_binding_affinity’, ‘selectivity_over_act’] — >50% null; excluded from MCDA to avoid mixing real vs. fallback scores

Cycle Health

• Agents reporting no progress: LEARNER, EXECUTOR (MCDA)
• Consecutive cycles with no new data or entities: 4
• Overall status: CRITICAL

Key Metrics

Metric	Value
Sources Reviewed	0
Budget Used Pct	9.61
Budget Remaining Usd	6.1569
Tasks Completed	1
Risks Identified	5

---

Agent Alert Levels

Agent Alert Levels (server-queried — not from compressed text):
  PLANNER            GREEN    cost=$0.0000  time=34s
  LEARNER            YELLOW   cost=$0.0000  time=6s
  EXECUTOR           YELLOW   cost=$0.0000  time=12s

A.G.E. Scores

(No AGE scores this cycle)

---

cycle_3 | index | cycle_5